Pre-clinical data also support the use of MET inhibitors, which induce enhanced helper T cell recognition of ENKTL cell lines and may be combined with immunotherapy [111], and oral MET inhibitors such as crizotinib have already been studied in other types of PTCL with an ORR of 90% in ALK-positive lymphomas [112]. Here, MET is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.